Literature DB >> 6185523

Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin.

D R Clemmons, L E Underwood, P G Chatelain, J J Van Wyk.   

Abstract

Most of the somatomedin in serum exists as a high molecular weight complex (approximately equal to 140,000) composed of binding protein subunits and small molecular weight somatomedin. These binding proteins may interfere with measurements of the somatomedins by various radioligand assays. In a companion paper, we reported that when serum is incubated at neutral pH the detectability of the somatomedin-C (Sm-C) is increased. Using gel chromatography, however, it was not possible to demonstrate release of free Sm-C from the macromolecular complex. In the studies reported here, incubation of heparinized plasma at pH 7.4 followed by gel chromatography in a heparin-containing buffer caused 70-80% of the immunoreactive Sm-C to shift from the gamma-globulin region to a molecular weight which approximates that of free Sm-C. This conversion is a time-dependent process which is inhibited by the proteolytic enzyme inhibitor antipain. Similar changes in the elution profile of Sm-C were observed when heparinized plasma was acidified and chromatographed in heparin. These findings suggest that 1) at neutral pH, serum proteolytic enzymes reduce the affinity between small molecular weight Sm-C and its binding proteins. 2) At acid pH, a similar effect is observed. 3) In the presence of heparin, reassociation of these components does not occur. These results suggest a possible mechanism whereby the somatomedin macromolecular complex could be disrupted so that small molecular weight somatomedin is made available to tissues.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6185523     DOI: 10.1210/jcem-56-2-384

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  The extracellular regulation of growth factor action.

Authors:  R Flaumenhaft; D B Rifkin
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

Review 2.  Somatomedins: chemical and functional characteristics of the different molecular forms.

Authors:  A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1989-04       Impact factor: 4.256

Review 3.  Somatomedin-binding proteins: what role do they play in the growth process?

Authors:  S Cianfarani; J M Holly
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

4.  Affinity-labeled plasma somatomedin-C/insulinlike growth factor I binding proteins. Evidence of growth hormone dependence and subunit structure.

Authors:  J R Wilkins; A J D'Ercole
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

5.  Collection of blood in heparinized tubes does not alter the molecular distribution or forms of IGFBP-3 and IGF.

Authors:  S Mandel; E Moreland; R G Rosenfeld; S E Gargosky
Journal:  Endocrine       Date:  1996-08       Impact factor: 3.633

6.  Glycosaminoglycans inhibit formation of the 140 kDa insulin-like growth factor-binding protein complex.

Authors:  R C Baxter
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

7.  Interaction of endothelial cell growth factor with heparin: characterization by receptor and antibody recognition.

Authors:  A B Schreiber; J Kenney; W J Kowalski; R Friesel; T Mehlman; T Maciag
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

Review 8.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

9.  Growth factor responses of human arterial endothelial cells in vitro.

Authors:  R Weinstein; K Wenc
Journal:  In Vitro Cell Dev Biol       Date:  1986-09

Review 10.  Insulin-like growth factors: Ligands, binding proteins, and receptors.

Authors:  Derek LeRoith; Jeff M P Holly; Briony E Forbes
Journal:  Mol Metab       Date:  2021-05-04       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.